Noxopharm Ltd. has released a press release.
Noxopharm progresses US regulatory strategy
Earlier from Noxopharm
- New data shows SOF-SKN active ingredient efficacy
- Innovative collaboration further expands Sofra platform
- March 2026 Quarterly Activities Report and Appendix 4C
- Positive SOF-SKN dosing data shows prolonged skin retention